CLYM

Climb Bio, Inc. (CLYM) - Q2 2026 10-Q Summary

Business Context and Reporting Period

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The reporting period covers the quarter and six months ended June 30, 2026. The company is classified as an emerging growth company and a smaller reporting company. Its primary pipeline includes budoprutug (anti-CD19) for indications such as primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), and CLYM116 (anti-APRIL) for immunoglobulin A nephropathy (IgAN).

Key Financial Metrics

Material Changes vs. Prior Period

• Financing Activity: In April 2026, the company completed a private placement raising approximately $103.4 million in net proceeds through the issuance of common stock and pre-funded warrants. This significantly bolstered liquidity compared to the prior year.
• Operating Expenses:
  • Quarterly: Total operating expenses increased by $4.7 million (44%) compared to Q2 2025, driven by increased spending on budoprutug and CLYM116 clinical programs and higher personnel costs.
  • Year-to-Date: Total operating expenses decreased by $3.1 million (9%) compared to YTD 2025. This decrease was primarily due to the absence of a $9.0 million upfront payment made in Q1 2025 for the CLYM116 license agreement, partially offset by increased clinical and personnel spend.
• Net Loss: Net loss for the quarter increased by $4.8 million due to higher operating expenses, while YTD net loss decreased by $2.2 million due to the timing of the CLYM116 upfront payment in the prior year.
• Interest Income: Interest income decreased slightly in both the quarter and YTD periods due to lower returns on marketable securities.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects the current cash balance of $239.2 million to fund operations into the second half of 2028. The company anticipates needing substantial additional financing in the future.
• Clinical Progress:
  • Budoprutug: Enrollment is ongoing in the Phase 2 PrisMN trial (pMN). Initial Phase 1b data for ITP was presented in June 2026, showing encouraging safety and efficacy. Phase 1b trials in SLE are ongoing globally and in China.
  • CLYM116: Phase 1 dosing in healthy volunteers was completed in June 2026. The partner, Mabworks, is conducting Phase 1/2 trials in China.
• Material Weaknesses: The company disclosed that disclosure controls and procedures were not effective as of June 30, 2026, due to two unremediated material weaknesses in internal control over financial reporting (lack of sufficient accounting personnel and lack of formal accounting policies/controls). Remediation efforts are underway.
• Legal Proceedings: A dispute remains pending with Alumis Inc. and Acelyrin regarding potential milestone payments under an asset purchase agreement.
• Risk Factors: Key risks include the need for additional capital, clinical trial uncertainties, reliance on third-party manufacturers (including single-source suppliers), and potential trade restrictions affecting Chinese partners (Mabworks) under the BIOSECURE Act and new tariffs.

Investor Verification Checklist

• Verify the timeline and sufficiency of the $239.2 million cash runway against the projected burn rate for clinical trials through 2028.
• Monitor the status of the unremediated material weaknesses in internal controls and the company's progress in hiring qualified accounting personnel.
• Review the outcome of the pending litigation with Alumis/Acelyrin regarding milestone payments.
• Assess the impact of U.S. trade policies (tariffs, BIOSECURE Act) on the company's reliance on Mabworks (China) for CLYM116 development and supply.
• Track upcoming data readouts for budoprutug in pMN, ITP, and SLE, and CLYM116 in IgAN, scheduled for late 2026 and 2027.